Scholars Central

Conference abstract

Nanoparticle-based targeting of integrin and#945;vand#946;3: Potential cancer and inflammation management and diagnosis

Authors: Paul J Davis

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Specific ligands of the extracellular domain of integrin αvβ3 include extracellular matrix proteins and nonpeptide hormones. The latter include thyroid hormone (L-thyroxine, T4; 3,5,3?-triiodo-L-thyronine, T3) and T4 analogue, tetraiodothyroacetic acid (tetrac). αvβ3 is generously expressed and activated in tumor cells and dividing endothelial cells. Targeting the thyroid hormone-tetrac receptor with nanoparticulate formulation of tetrac?in which tetrac is covalently bound to poly(lactic-coglycolic acid) (PLGA)?enables modulation of cancer defense pathways, tumor-relevant angiogenesis and nonmalignant angiogenesis at sites of inflammation/infection. The tetrac may be radiolabeled to create diagnostic imaging products for tumor or inflammation. Further, the PLGA, itself, may be loaded with a traditional cancer chemotherapeutic agent, with anti-inflammatory agents (NSAIDS) or anti-infectives; the agent(s) will be locally unloaded when the tetrac-integrin complex is formed at the tumor or inflammation site, affording high local drug concentrations and reduced systemic drug exposure, compared to conventional administration. Bone-resorbing osteoclasts are a final class of cells that express large quantities of αvβ3 and this population of cells offers opportunities for treatment of bone mass loss and for diagnosis and management of local bone resorption. This presentation examines the advantages and liabilities of the options afforded by nanoparticle-based targeting of αvβ3 and discusses other therapeutic and diagnostic options that may be offered by such agents. PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Stem Cell Research & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Paul J Davis”